<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:media="http://search.yahoo.com/mrss/" xmlns:podcast="https://podcastindex.org/namespace/1.0">
  <channel>
    <atom:link href="https://feeds.simplecast.com/OLtcmjL2" rel="self" title="MP3 Audio" type="application/atom+xml"/>
    <atom:link href="https://simplecast.superfeedr.com" rel="hub" xmlns="http://www.w3.org/2005/Atom"/>
    <generator>https://simplecast.com</generator>
    <title>Decera Clinical Education Pharmacy Practice Podcast</title>
    <description>Enhance your pharmacy practice with ProCE’s up-to-date, clinically relevant, and evidence-based education across a variety of therapeutic areas.</description>
    <copyright>2021 ProCE Podcast</copyright>
    <language>en</language>
    <pubDate>Tue, 12 Aug 2025 14:50:07 +0000</pubDate>
    <lastBuildDate>Tue, 2 Dec 2025 15:22:58 +0000</lastBuildDate>
    <image>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com</link>
      <title>Decera Clinical Education Pharmacy Practice Podcast</title>
      <url>https://image.simplecastcdn.com/images/9a6b9d67-7096-496d-ac5c-801628147144/0beb31f1-3f40-4064-9189-93600d1ee922/3000x3000/proce-podcast-show-icon-final.jpg?aid=rss_feed</url>
    </image>
    <link>https://proce-the-pharmacy-practice-podcast.simplecast.com</link>
    <itunes:type>episodic</itunes:type>
    <itunes:summary>Enhance your pharmacy practice with ProCE’s up-to-date, clinically relevant, and evidence-based education across a variety of therapeutic areas.</itunes:summary>
    <itunes:author>ProCE</itunes:author>
    <itunes:explicit>false</itunes:explicit>
    <itunes:image href="https://image.simplecastcdn.com/images/9a6b9d67-7096-496d-ac5c-801628147144/0beb31f1-3f40-4064-9189-93600d1ee922/3000x3000/proce-podcast-show-icon-final.jpg?aid=rss_feed"/>
    <itunes:new-feed-url>https://feeds.simplecast.com/OLtcmjL2</itunes:new-feed-url>
    <itunes:keywords>pharmacy, ce podcast, pharmacist, pharmacy education, pharmacy practice</itunes:keywords>
    <itunes:owner>
      <itunes:name>ProCE</itunes:name>
      <itunes:email>support@clinicaloptions.com</itunes:email>
    </itunes:owner>
    <itunes:category text="Education">
      <itunes:category text="Courses"/>
    </itunes:category>
    <itunes:category text="Health &amp; Fitness">
      <itunes:category text="Medicine"/>
    </itunes:category>
    <itunes:category text="Science">
      <itunes:category text="Life Sciences"/>
    </itunes:category>
    <item>
      <guid isPermaLink="false">c8037517-1c1f-4f10-823b-089d84113a36</guid>
      <title>Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective</title>
      <description><![CDATA[<p>In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:</p><ul><li>Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules</li><li>Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations</li><li>Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations</li></ul><p><strong>Presenters:</strong></p><p><strong>Kelly Romo, PharmD, BCOP</strong><br />Manager, Oncology Medical Drug Management and Customer Initiatives<br />Blue Cross Blue Shield Michigan<br />Detroit, Michigan</p><p><strong>Shawna Kraft, PharmD, BCOP</strong><br />Clinical Pharmacist, Specialist<br />Michigan Medicine, Rogel Cancer Center<br />Clinical Associate Professor<br />University of Michigan College of Pharmacy<br />Ann Arbor, Michigan</p><p><strong>Resources:</strong><br />Consolidate your learning with a recording from an <a href="https://bit.ly/4mdczGb" target="_blank">on-demand webcast</a>, download the <a href="https://bit.ly/45xwAAf" target="_blank">slides</a> associated with this discussion, or read an expert <a href="https://bit.ly/45qrMMU" target="_blank">text module</a> or <a href="https://bit.ly/45qrMMU" target="_blank">commentary</a> on this topic. </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 12 Aug 2025 14:50:07 +0000</pubDate>
      <author>support@clinicaloptions.com (Kelly Romo PharmD BCOP, Shawna Kraft PharmD BCOP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/subcutaneous-io-podcast-aFoRXdqN</link>
      <content:encoded><![CDATA[<p>In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:</p><ul><li>Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules</li><li>Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations</li><li>Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations</li></ul><p><strong>Presenters:</strong></p><p><strong>Kelly Romo, PharmD, BCOP</strong><br />Manager, Oncology Medical Drug Management and Customer Initiatives<br />Blue Cross Blue Shield Michigan<br />Detroit, Michigan</p><p><strong>Shawna Kraft, PharmD, BCOP</strong><br />Clinical Pharmacist, Specialist<br />Michigan Medicine, Rogel Cancer Center<br />Clinical Associate Professor<br />University of Michigan College of Pharmacy<br />Ann Arbor, Michigan</p><p><strong>Resources:</strong><br />Consolidate your learning with a recording from an <a href="https://bit.ly/4mdczGb" target="_blank">on-demand webcast</a>, download the <a href="https://bit.ly/45xwAAf" target="_blank">slides</a> associated with this discussion, or read an expert <a href="https://bit.ly/45qrMMU" target="_blank">text module</a> or <a href="https://bit.ly/45qrMMU" target="_blank">commentary</a> on this topic. </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="23829615" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/89a12c88-64c7-48b0-9c39-bdfade4b1ac0/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=89a12c88-64c7-48b0-9c39-bdfade4b1ac0&amp;feed=OLtcmjL2"/>
      <itunes:title>Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective</itunes:title>
      <itunes:author>Kelly Romo PharmD BCOP, Shawna Kraft PharmD BCOP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/a71e1a85-5842-45d5-91c9-04332da3be87/3000x3000/proce-101002-multitumor-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:24:49</itunes:duration>
      <itunes:summary>Listen to this podcast with clinical and managed care pharmacy expert perspectives on  the use of available and emerging subcutaneous immunotherapy options for patients with cancer.</itunes:summary>
      <itunes:subtitle>Listen to this podcast with clinical and managed care pharmacy expert perspectives on  the use of available and emerging subcutaneous immunotherapy options for patients with cancer.</itunes:subtitle>
      <itunes:keywords>pros, relatlimab, human hyaluronidase, nivolumab, breast cancers, pembrolizumab, subcutaneous immunotherapy, renal cell carcinoma, intravenous, clinical pharmacy, nsclc, pharmd, kelly romo, shawna kraft, melanoma, patient reported outcomes, ipilimumab, rcc, managed care, subcutaneous, relativity-127, atezolizumab, bcop, bcop</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>23</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">8dc2969a-5ffc-47c3-abfc-690ff3724d54</guid>
      <title>What Oncology Pharmacists Need to Know About ADCs in Solid Tumor Management</title>
      <description><![CDATA[<p>In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:</p><ul><li>An overview of ADC structure and mechanism of action</li><li>A topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor types</li><li>An in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategies</li></ul><p><i><strong>Editor’s note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy. </strong></i></p><p><strong>Program faculty:</strong></p><p><strong>Allison Butts, PharmD, BCOP</strong><br />Pharmacist Manager, Oncology<br />Clinical Pharmacist, Breast Oncology<br />UK HealthCare<br />Markey Cancer Center<br />Lexington, Kentucky</p><p><strong>Danielle Roman, PharmD, BCOP</strong><br />Manager, Oncology Clinical Pharmacy Services<br />Allegheny Health Network<br />Pittsburgh, Pennsylvania</p><p><strong>Program page:</strong><br /><a href="https://bit.ly/4lr7cT6" target="_blank">https://bit.ly/4lr7cT6</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 27 Jun 2025 17:18:32 +0000</pubDate>
      <author>support@clinicaloptions.com (Allison Butts PharmD BCOP, Danielle Roman PharmD BCOP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/what-oncology-pharmacists-need-to-know-about-adcs-in-solid-tumor-management-9KrkeRbr</link>
      <content:encoded><![CDATA[<p>In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:</p><ul><li>An overview of ADC structure and mechanism of action</li><li>A topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor types</li><li>An in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategies</li></ul><p><i><strong>Editor’s note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy. </strong></i></p><p><strong>Program faculty:</strong></p><p><strong>Allison Butts, PharmD, BCOP</strong><br />Pharmacist Manager, Oncology<br />Clinical Pharmacist, Breast Oncology<br />UK HealthCare<br />Markey Cancer Center<br />Lexington, Kentucky</p><p><strong>Danielle Roman, PharmD, BCOP</strong><br />Manager, Oncology Clinical Pharmacy Services<br />Allegheny Health Network<br />Pittsburgh, Pennsylvania</p><p><strong>Program page:</strong><br /><a href="https://bit.ly/4lr7cT6" target="_blank">https://bit.ly/4lr7cT6</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="32567486" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/79a32e6e-326b-4424-9314-e2571297cfd3/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=79a32e6e-326b-4424-9314-e2571297cfd3&amp;feed=OLtcmjL2"/>
      <itunes:title>What Oncology Pharmacists Need to Know About ADCs in Solid Tumor Management</itunes:title>
      <itunes:author>Allison Butts PharmD BCOP, Danielle Roman PharmD BCOP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/ec61b327-3a4f-4bed-a4d2-7c7d2df62891/620af98c-018d-48c2-b281-d7e8e0b7013f/3000x3000/proce-100245-multitumor-adc-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:33:55</itunes:duration>
      <itunes:summary>An audio podcast with expert insights on what oncology pharmacists need to know to safely and effectively incorporate ADCs into solid tumor management.</itunes:summary>
      <itunes:subtitle>An audio podcast with expert insights on what oncology pharmacists need to know to safely and effectively incorporate ADCs into solid tumor management.</itunes:subtitle>
      <itunes:keywords>destiny-breast06, tropics-02, antibody drug conjugates, trastuzumab emtansine, pneumonitis, t-dm1, destiny-breast04, multi tumor, adverse events, destiny-breast03, destiny-gastric01, tropion-breast01, ascent, her2, adverse event management, sacituzumab govitecan, trop-2, t-dxd, ild, trastuzumab deruxtecan, destiny-lung02, aes, adc, datopotamab deruxtecan</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>22</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">9808f688-b309-4d4d-8bdf-8f1cc0e76a3c</guid>
      <title>Innovations in NCFBE: Understanding the Patient Burden and Best Practices in Diagnostics</title>
      <description><![CDATA[<p>In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including:</p><ul><li>The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection)</li><li>Cough as the most significant symptom and burden</li><li>Imaging bronchiectasis with classic and inflammatory findings</li><li>Differentiating the causes of NCFBE to inform patient care</li></ul><p><strong>Presenters</strong></p><p><strong>Brett M. Elicker, MD</strong><br />Professor of Clinical Radiology<br />Chief, Cardiothoracic Imaging Division<br />Department of Radiology & Biomedical Imaging<br />University of California, San Francisco<br />San Francisco, California</p><p><strong>David E. Griffith, MD, ATSF, FACCP, FRSM</strong><br />Professor of Medicine<br />Division of Mycobacterial and Respiratory Diseases<br />Department of Medicine<br />National Jewish Health<br />Denver, Colorado</p><p><strong>Program page</strong>: <br /><a href="https://bit.ly/4mZbYsm" target="_blank">https://bit.ly/4mZbYsm</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 18 Jun 2025 18:22:11 +0000</pubDate>
      <author>support@clinicaloptions.com (Brett M. Elicker MD, David E. Griffith MD ATSF FACCP FRSM)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/innovations-in-ncfbe-podcast-1-jbn6PN8e</link>
      <content:encoded><![CDATA[<p>In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including:</p><ul><li>The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection)</li><li>Cough as the most significant symptom and burden</li><li>Imaging bronchiectasis with classic and inflammatory findings</li><li>Differentiating the causes of NCFBE to inform patient care</li></ul><p><strong>Presenters</strong></p><p><strong>Brett M. Elicker, MD</strong><br />Professor of Clinical Radiology<br />Chief, Cardiothoracic Imaging Division<br />Department of Radiology & Biomedical Imaging<br />University of California, San Francisco<br />San Francisco, California</p><p><strong>David E. Griffith, MD, ATSF, FACCP, FRSM</strong><br />Professor of Medicine<br />Division of Mycobacterial and Respiratory Diseases<br />Department of Medicine<br />National Jewish Health<br />Denver, Colorado</p><p><strong>Program page</strong>: <br /><a href="https://bit.ly/4mZbYsm" target="_blank">https://bit.ly/4mZbYsm</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="22688422" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/25546314-c865-4d61-8d81-1a5f30178ee6/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=25546314-c865-4d61-8d81-1a5f30178ee6&amp;feed=OLtcmjL2"/>
      <itunes:title>Innovations in NCFBE: Understanding the Patient Burden and Best Practices in Diagnostics</itunes:title>
      <itunes:author>Brett M. Elicker MD, David E. Griffith MD ATSF FACCP FRSM</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/446d6420-3a4d-444e-a1f2-72f9bd648021/3000x3000/proce-100528-ncfbe-ats-pod1-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:23:32</itunes:duration>
      <itunes:summary>Listen in as a respiratory diseases expert and radiology expert discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE.</itunes:summary>
      <itunes:subtitle>Listen in as a respiratory diseases expert and radiology expert discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE.</itunes:subtitle>
      <itunes:keywords>bronchiectasis, internal medicine, radiology, non–cystic fibrosis bronchiectasis, ncfbe, cystic fibrosis, non-cystic fibrosis bronchiectasis, pulmonology</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>21</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">4d5466c7-5c5e-4f00-897e-0b724cde838d</guid>
      <title>Systemic Mastocytosis: Pharmacist-Focused Strategies to Improve Patient Outcomes</title>
      <description><![CDATA[<p>Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including:</p><ul><li>Strategies to better identify patients presenting with features of SM to facilitate timely diagnosis</li><li>Current guideline-recommended treatment approaches</li><li>Emerging data on new targeted agents for SM</li><li>Pharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education)</li></ul><p><strong>Presenters</strong><br />Jonathan A. Bernstein, MD<br />Professor of Medicine<br />Division of Rheumatology, Allergy and Immunology<br />Department of Internal Medicine<br />University of Cincinnati College of Medicine<br />Partner Advanced Allergy Services, LLC<br />Partner Bernstein Clinical Research Center, LLC<br />Cincinnati, Ohio</p><p>Ryan Haumschild, PharmD, MS, MBA, CPEL<br />Vice President of Pharmacy, Ambulatory<br />Emory Healthcare<br />Winship Cancer Institute<br />Atlanta, Georgia</p><p>Full link to program page:<br /><a href="https://bit.ly/3HcA8z2" target="_blank">https://bit.ly/3HcA8z2</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 16 May 2025 15:04:03 +0000</pubDate>
      <author>support@clinicaloptions.com (Jonathan A. Bernstein MD, Ryan Haumschild PharmD MS MBA CPEL)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/systemic-mastocytosis-pharmacist-focused-strategies-to-improve-patient-outcomes-4fpU0CAs</link>
      <content:encoded><![CDATA[<p>Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including:</p><ul><li>Strategies to better identify patients presenting with features of SM to facilitate timely diagnosis</li><li>Current guideline-recommended treatment approaches</li><li>Emerging data on new targeted agents for SM</li><li>Pharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education)</li></ul><p><strong>Presenters</strong><br />Jonathan A. Bernstein, MD<br />Professor of Medicine<br />Division of Rheumatology, Allergy and Immunology<br />Department of Internal Medicine<br />University of Cincinnati College of Medicine<br />Partner Advanced Allergy Services, LLC<br />Partner Bernstein Clinical Research Center, LLC<br />Cincinnati, Ohio</p><p>Ryan Haumschild, PharmD, MS, MBA, CPEL<br />Vice President of Pharmacy, Ambulatory<br />Emory Healthcare<br />Winship Cancer Institute<br />Atlanta, Georgia</p><p>Full link to program page:<br /><a href="https://bit.ly/3HcA8z2" target="_blank">https://bit.ly/3HcA8z2</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="29876297" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/bc73bd27-ebc1-4115-ba2a-96b39d4778f8/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=bc73bd27-ebc1-4115-ba2a-96b39d4778f8&amp;feed=OLtcmjL2"/>
      <itunes:title>Systemic Mastocytosis: Pharmacist-Focused Strategies to Improve Patient Outcomes</itunes:title>
      <itunes:author>Jonathan A. Bernstein MD, Ryan Haumschild PharmD MS MBA CPEL</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/ec61b327-3a4f-4bed-a4d2-7c7d2df62891/0c3dc342-ffb5-484d-9220-c5617924b5ab/3000x3000/100333-ism-pharmacy-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:30:59</itunes:duration>
      <itunes:summary>Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss approaches to managing systemic mastocytosis—from earlier recognition and diagnosis to the use of emerging targeted therapies—that can reduce disease burden and improve outcomes for patients.</itunes:summary>
      <itunes:subtitle>Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss approaches to managing systemic mastocytosis—from earlier recognition and diagnosis to the use of emerging targeted therapies—that can reduce disease burden and improve outcomes for patients.</itunes:subtitle>
      <itunes:keywords>national comprehensive cancer network guidelines, aggressive sm, aggressive systemic mastocytosis, indolent sm, kit inhibitor, allergy, mastinib, systemic mastocytosis, mcl, neoplastic disorder, hematologic malignancy, imatinib, smoldering sm, cytoreductive therapy, dermatology, tyrosine kinase inhibitor, asm, hematologic malignancies, mast cell leukemia, systemic mastocytosis with associated hematologic neoplasm, elenesitinib, avapritinib, bone marrow mastocytosis, mastocytosis, kit d816v, immunology, antimediator therapy, who criteria, bezuclastinib, advanced systemic mastocytosis, heme malignancy, smoldering systemic mastocystosis, midostuarin, nccn guidelines, international consensus classification, tl-895, hematology, heme malignancies, sm, tki, ism, indolent systemic mastocytosis, advanced sm, kinase inhibitor, sm with associated hematologic neoplasm, ssm, evidence-based care, world health organization criteria, bmm, kit</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>20</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">a058e0fb-3213-4766-a6bb-01c6aaa4e1a0</guid>
      <title>How Pharmacists Can Enhance Comprehensive Patient-Centered Care for Patients With HR+/HER2- MBC and Comorbidities</title>
      <description><![CDATA[<p>In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:</p><ul><li>Common comorbidities and complexities in managing patients with HR+/HER2- MBC</li><li>Treatment landscape for patients with HR+/HER2- MBC</li><li>Real-world studies in women with HR+/HER2- MBC</li><li>Mitigation and management of drug interactions and multidisciplinary team coordination treatment selection</li><li>Patient goals and coordinating with multidisciplinary team to maximize quality of life</li></ul><p>Link to full program:<br /><a href="https://bit.ly/4jCQe38" target="_blank">https://bit.ly/4jCQe38</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 29 Apr 2025 17:15:00 +0000</pubDate>
      <author>support@clinicaloptions.com (Allison Butts PharmD BCOP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/pharmacist-care-of-hrpos-her2neg-mbc-with-comorbidities-6EUEUXpS</link>
      <content:encoded><![CDATA[<p>In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:</p><ul><li>Common comorbidities and complexities in managing patients with HR+/HER2- MBC</li><li>Treatment landscape for patients with HR+/HER2- MBC</li><li>Real-world studies in women with HR+/HER2- MBC</li><li>Mitigation and management of drug interactions and multidisciplinary team coordination treatment selection</li><li>Patient goals and coordinating with multidisciplinary team to maximize quality of life</li></ul><p>Link to full program:<br /><a href="https://bit.ly/4jCQe38" target="_blank">https://bit.ly/4jCQe38</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="16095558" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/b7f8ba46-2799-4cc4-bb82-13c29117fc5c/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=b7f8ba46-2799-4cc4-bb82-13c29117fc5c&amp;feed=OLtcmjL2"/>
      <itunes:title>How Pharmacists Can Enhance Comprehensive Patient-Centered Care for Patients With HR+/HER2- MBC and Comorbidities</itunes:title>
      <itunes:author>Allison Butts PharmD BCOP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/37639571-1cd3-41d6-bf4d-5a55fe5ee63c/3000x3000/proce-100738-mbc-hr-her2-pod1-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:16:41</itunes:duration>
      <itunes:summary>Listen to Allison Butts, PharmD, BCOP, review key highlights from a virtual live webinar on optimal approaches to ensure that comprehensive patient-centric care is provided for patients with HR+/HER2- metastatic breast cancer and various other comorbidities.</itunes:summary>
      <itunes:subtitle>Listen to Allison Butts, PharmD, BCOP, review key highlights from a virtual live webinar on optimal approaches to ensure that comprehensive patient-centric care is provided for patients with HR+/HER2- metastatic breast cancer and various other comorbidities.</itunes:subtitle>
      <itunes:keywords>abemaciclib, pik3ca mutation, metastatic breast cancer, inavo120, breast cancer, qtc prolongation, her2 negative breast cancer, mbc, advanced breast cancer, paloma-2, palbociclib, hormone receptor positive, inavolisib, ribociclib, p-reality x, real-world evidence, cdk4/6 inhibitor, cdk4/6i</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>19</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">e978acea-3526-475b-9a46-69e74d79513b</guid>
      <title>Navigating Immune-Related Toxicities: Insights on Monitoring, Treatment, and Prevention</title>
      <description><![CDATA[<p>In this episode, Alexa Basilio, PharmD, BCOP and Jessica Davis, PharmD, BCOP, CPP discuss immune-related adverse events and toxicities among patients using immune checkpoint inhibitors. This overview will include discussion about: </p><ul><li>How and when to monitor and treat mild vs severe immune-related toxicities</li><li>The art of balancing and tapering low-dose and high-dose corticosteroids</li><li>Differentiating between immune-related and chemotherapy- or targeted therapy–associated adverse events for optimal management approaches</li><li>Involvement of multidisciplinary teams early during treatment to prevent immune-related adverse events</li><li>Importance of educating patients, caregivers, and providers on immune-related toxicities</li></ul><p><br /><strong>Presenters: </strong></p><p><strong>Alexa Basilio, PharmD, BCOP</strong><br />University of Florida College of Pharmacy <br />Oncology Pharmacy Specialist <br />McKesson, The US Oncology Network<br />Tampa, Florida </p><p><strong>Jessica Davis, PharmD, BCOP, CPP </strong><br />Levine Cancer Institute<br />Clinical Pharmacist Coordinator, Adult Hematology/Oncology<br />Atrium Health Levine Center<br />Charlotte, North Carolina </p><p>Link to full program: <br /><a href="https://bit.ly/3We4HJy" target="_blank">https://bit.ly/3We4HJy</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 10 Jan 2025 20:35:53 +0000</pubDate>
      <author>support@clinicaloptions.com (Alexa Basilio PharmD BCOP, Jessica Davis PharmD BCOP CPP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/navigating-immune-related-toxicities-rwDsqjhW</link>
      <content:encoded><![CDATA[<p>In this episode, Alexa Basilio, PharmD, BCOP and Jessica Davis, PharmD, BCOP, CPP discuss immune-related adverse events and toxicities among patients using immune checkpoint inhibitors. This overview will include discussion about: </p><ul><li>How and when to monitor and treat mild vs severe immune-related toxicities</li><li>The art of balancing and tapering low-dose and high-dose corticosteroids</li><li>Differentiating between immune-related and chemotherapy- or targeted therapy–associated adverse events for optimal management approaches</li><li>Involvement of multidisciplinary teams early during treatment to prevent immune-related adverse events</li><li>Importance of educating patients, caregivers, and providers on immune-related toxicities</li></ul><p><br /><strong>Presenters: </strong></p><p><strong>Alexa Basilio, PharmD, BCOP</strong><br />University of Florida College of Pharmacy <br />Oncology Pharmacy Specialist <br />McKesson, The US Oncology Network<br />Tampa, Florida </p><p><strong>Jessica Davis, PharmD, BCOP, CPP </strong><br />Levine Cancer Institute<br />Clinical Pharmacist Coordinator, Adult Hematology/Oncology<br />Atrium Health Levine Center<br />Charlotte, North Carolina </p><p>Link to full program: <br /><a href="https://bit.ly/3We4HJy" target="_blank">https://bit.ly/3We4HJy</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="28932395" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/6f3fdb13-1367-420f-8b27-f612ddd8300e/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=6f3fdb13-1367-420f-8b27-f612ddd8300e&amp;feed=OLtcmjL2"/>
      <itunes:title>Navigating Immune-Related Toxicities: Insights on Monitoring, Treatment, and Prevention</itunes:title>
      <itunes:author>Alexa Basilio PharmD BCOP, Jessica Davis PharmD BCOP CPP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/29122c84-7b0e-4293-ba9f-8df030b00f47/3000x3000/100023-multitumor-irae-wc-pharm-01.jpg?aid=rss_feed"/>
      <itunes:duration>00:30:03</itunes:duration>
      <itunes:summary>In this episode, Jessica Davis, PharmD, and Alexa Basilio, PharmD, explore the complexities of immune-related toxicities, offering expert insights on how to monitor, treat, and prevent these adverse events.</itunes:summary>
      <itunes:subtitle>In this episode, Jessica Davis, PharmD, and Alexa Basilio, PharmD, explore the complexities of immune-related toxicities, offering expert insights on how to monitor, treat, and prevent these adverse events.</itunes:subtitle>
      <itunes:keywords>relatlimab, avelumab, genitourinary cancers, immune-related adverse effects, dostarlimab, nivolumab, pembrolizumab, cemiplimab, tremelimumab, irae, tislelizumab, immune checkpoint inhibitors, retifanlimab, immune-related adverse events, supportive care, skin cancers, lung cancers, ici, ipilimumab, oncology, hematology, immune-related toxicities, gastrointestinal cancers, head and neck cancers, gynecologic cancers, corticosteroids, durvalumab, cancer, atezolizumab</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>18</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">bdf309fe-df90-4ecd-9088-efe255112289</guid>
      <title>How Primary Care Providers Can Expand Their Role in HBV Management</title>
      <description><![CDATA[<p>In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:</p><ul><li>Engage key stakeholders in the provision of HBV care​</li><li>Provide HBV management resources to support PCPs who are doing screening​</li><li>Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBV</li></ul><p>Presenters:</p><p><strong>Su Wang, MD, MPH, FACP</strong><br />Medical Director<br />Center for Asian Health and Viral Hepatitis Programs<br />Cooperman Barnabas Medical Center<br />RWJBarnabas-Rutgers Medical Group<br />Associate Member<br />Health Care Policy and Aging Research<br />The Rutgers Institute for Health<br />Senior Advisor<br />Global Health, Hepatitis B Foundation<br />Florham Park, New Jersey</p><p><strong>Richard R. Andrews, MD, MPH</strong><br />President, Houston Viral Hepatitis Task Force<br />Former Co-Chair, National Task Force on Hepatitis B<br />Board-Certified Family Medicine<br />Addiction Medicine Physician<br />Houston, Texas</p><p><strong>Ruth Brogden, MPH</strong><br />Patient Advocate</p><p><strong>Amy S. Tang, MD</strong><br />Former Co-Chair, National Task Force on Hepatitis B<br />Director of Immigrant Health<br />North East Medical Services<br />San Francisco, California</p><p>Link to full program: <br /><a href="https://bit.ly/3TuqFHI" target="_blank">https://bit.ly/3TuqFHI</a></p><p>Link to the slides:<br /><a href="https://bit.ly/44hXpHu" target="_blank">https://bit.ly/44hXpHu</a></p><p>Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 26 Apr 2024 16:24:45 +0000</pubDate>
      <author>support@clinicaloptions.com (Su Wang MD MPH FACP, Richard R. Andrews MD, Ruth Brogden MPH, Amy S. Tang MD)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/primary-care-hbv-management-oW76_TSr</link>
      <content:encoded><![CDATA[<p>In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:</p><ul><li>Engage key stakeholders in the provision of HBV care​</li><li>Provide HBV management resources to support PCPs who are doing screening​</li><li>Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBV</li></ul><p>Presenters:</p><p><strong>Su Wang, MD, MPH, FACP</strong><br />Medical Director<br />Center for Asian Health and Viral Hepatitis Programs<br />Cooperman Barnabas Medical Center<br />RWJBarnabas-Rutgers Medical Group<br />Associate Member<br />Health Care Policy and Aging Research<br />The Rutgers Institute for Health<br />Senior Advisor<br />Global Health, Hepatitis B Foundation<br />Florham Park, New Jersey</p><p><strong>Richard R. Andrews, MD, MPH</strong><br />President, Houston Viral Hepatitis Task Force<br />Former Co-Chair, National Task Force on Hepatitis B<br />Board-Certified Family Medicine<br />Addiction Medicine Physician<br />Houston, Texas</p><p><strong>Ruth Brogden, MPH</strong><br />Patient Advocate</p><p><strong>Amy S. Tang, MD</strong><br />Former Co-Chair, National Task Force on Hepatitis B<br />Director of Immigrant Health<br />North East Medical Services<br />San Francisco, California</p><p>Link to full program: <br /><a href="https://bit.ly/3TuqFHI" target="_blank">https://bit.ly/3TuqFHI</a></p><p>Link to the slides:<br /><a href="https://bit.ly/44hXpHu" target="_blank">https://bit.ly/44hXpHu</a></p><p>Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="18206326" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/78f5d748-48e2-4cdb-8f97-1b6cbf97cf7d/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=78f5d748-48e2-4cdb-8f97-1b6cbf97cf7d&amp;feed=OLtcmjL2"/>
      <itunes:title>How Primary Care Providers Can Expand Their Role in HBV Management</itunes:title>
      <itunes:author>Su Wang MD MPH FACP, Richard R. Andrews MD, Ruth Brogden MPH, Amy S. Tang MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/72b9dc29-1826-4dd8-9508-4e03398e5a78/3000x3000/proce-5673-hbv-early-pod3-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:18:52</itunes:duration>
      <itunes:summary>Listen as Su Wang, MD, MPH, FACP; Richard R. Andrews, MD, MPH; Ruth Brogden, MPH; and Amy S. Tang, MD, explore how early and sustained HBV care can be enhanced by expanding the role of primary care providers.</itunes:summary>
      <itunes:subtitle>Listen as Su Wang, MD, MPH, FACP; Richard R. Andrews, MD, MPH; Ruth Brogden, MPH; and Amy S. Tang, MD, explore how early and sustained HBV care can be enhanced by expanding the role of primary care providers.</itunes:subtitle>
      <itunes:keywords>primary care provider, hbsag, hepatocellular carcinoma, chronic hepatitis b, primary care, chb, hbv, pcp, hcc, hepatitis b surface antigen, hepatitis b virus, shared decision-making</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>17</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">75e58598-719e-4784-b967-bbafd7a87f06</guid>
      <title>How to Implement Earlier Hepatitis B Treatment</title>
      <description><![CDATA[<p>In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:</p><ul><li>Patient subgroups to consider for treatment outside guideline criteria</li><li>Adverse event and cost-effectiveness considerations</li><li>Integration of patient perspectives in wider treatment</li></ul><p>Presenters:</p><p><strong>Mark S. Sulkowski, MD, FIDSA, FAASLD</strong><br />Professor of Medicine<br />Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center<br />Johns Hopkins University School of Medicine<br />Baltimore, Maryland</p><p><strong>Tatyana Kushner, MD, MSCE</strong><br />Associate Professor<br />Division of Liver Diseases<br />Icahn School of Medicine at Mount Sinai<br />New York, New York</p><p><strong>Paul Y. Kwo, MD</strong><br />Professor of Medicine<br />Director of Hepatology<br />Stanford University School of Medicine<br />Palo Alto, California</p><p><strong>Jacki Chen, PhD</strong><br />Patient Advocate </p><p>Link to full program: <br /><a href="https://bit.ly/3TuqFHI" target="_blank">https://bit.ly/3TuqFHI</a></p><p>Link to the slides:<br /><a href="https://bit.ly/4a60GM4" target="_blank">https://bit.ly/4a60GM4</a></p><p>Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 26 Mar 2024 18:31:51 +0000</pubDate>
      <author>support@clinicaloptions.com (Mark S. Sulkowski MD FIDSA FAASLD, Tatyana Kushner MD MSCE, Paul Y. Kwo MD, Jacki Chen PhD)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/early-hbv-treatment-3GhIdIyy</link>
      <content:encoded><![CDATA[<p>In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:</p><ul><li>Patient subgroups to consider for treatment outside guideline criteria</li><li>Adverse event and cost-effectiveness considerations</li><li>Integration of patient perspectives in wider treatment</li></ul><p>Presenters:</p><p><strong>Mark S. Sulkowski, MD, FIDSA, FAASLD</strong><br />Professor of Medicine<br />Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center<br />Johns Hopkins University School of Medicine<br />Baltimore, Maryland</p><p><strong>Tatyana Kushner, MD, MSCE</strong><br />Associate Professor<br />Division of Liver Diseases<br />Icahn School of Medicine at Mount Sinai<br />New York, New York</p><p><strong>Paul Y. Kwo, MD</strong><br />Professor of Medicine<br />Director of Hepatology<br />Stanford University School of Medicine<br />Palo Alto, California</p><p><strong>Jacki Chen, PhD</strong><br />Patient Advocate </p><p>Link to full program: <br /><a href="https://bit.ly/3TuqFHI" target="_blank">https://bit.ly/3TuqFHI</a></p><p>Link to the slides:<br /><a href="https://bit.ly/4a60GM4" target="_blank">https://bit.ly/4a60GM4</a></p><p>Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="20656555" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/337347e3-3d5b-4470-8261-2bb0754e5750/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=337347e3-3d5b-4470-8261-2bb0754e5750&amp;feed=OLtcmjL2"/>
      <itunes:title>How to Implement Earlier Hepatitis B Treatment</itunes:title>
      <itunes:author>Mark S. Sulkowski MD FIDSA FAASLD, Tatyana Kushner MD MSCE, Paul Y. Kwo MD, Jacki Chen PhD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/3b16bcea-acdb-4d95-bd9f-fb4fb6d70d3f/3000x3000/proce-5673-hbv-early-pod2-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:21:27</itunes:duration>
      <itunes:summary>Listen as Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, review strategies for more expansive HBV treatment while considering adverse events, cost-effectiveness, and patient perspectives. </itunes:summary>
      <itunes:subtitle>Listen as Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, review strategies for more expansive HBV treatment while considering adverse events, cost-effectiveness, and patient perspectives. </itunes:subtitle>
      <itunes:keywords>treatment, kushner, jacki, apasl, antivirals, viral hepatitis, entecavir, kwo, tenofovir alafenamide, aasld, sulkowski, hepatitis b, hepatitis, tenofovir disoproxil fumarate, interferon, tdf, guideline-based treatment, easl, hbv, implementation, antiviral treatment, guideline, taf, hepatitis b virus, tenofovir, peg-interferon, vemlidy</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>16</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">bce8558b-3b50-4099-88a6-f9a4d721794d</guid>
      <title>How to Implement Earlier Hepatitis B and Hepatitis Delta Screening</title>
      <description><![CDATA[<p>In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:</p><ul><li>Updated CDC recommendations for one-time universal screening for HBV</li><li>Addressing patient-, provider-, and system-level barriers to universal HBV screening</li><li>Best practices for implementation of HDV screening</li></ul><p>Presenters:</p><p><strong>Douglas Dieterich, MD</strong><br />Director, Institute for Liver Medicine</p><p>Professor of Medicine</p><p>Division of Liver Diseases</p><p>Mount Sinai School of Medicine</p><p>New York, New York</p><p><strong>Camilla S. Graham, MD, MPH</strong><br />Co-Director, Viral Hepatitis Clinic<br />Division of Infectious Diseases<br />Beth Israel Deaconess Medical Center<br />Harvard Medical School<br />Boston, Massachusetts</p><p><strong>Robert Wong, MD, MS </strong><br />Clinical Associate Professor<br />Division of Gastroenterology and Hepatology<br />Stanford University School of Medicine<br />Palo Alto, California</p><p>Link to full program:<br /><a href="https://bit.ly/3TuqFHI" target="_blank">https://bit.ly/3TuqFHI</a></p><p>Link to the slides: <br /><a href="https://bit.ly/4atS42z" target="_blank">https://bit.ly/4atS42z</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 22 Dec 2023 05:00:00 +0000</pubDate>
      <author>support@clinicaloptions.com (ProCE)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/early-hbv-and-hdv-screening-xayduA1m</link>
      <content:encoded><![CDATA[<p>In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:</p><ul><li>Updated CDC recommendations for one-time universal screening for HBV</li><li>Addressing patient-, provider-, and system-level barriers to universal HBV screening</li><li>Best practices for implementation of HDV screening</li></ul><p>Presenters:</p><p><strong>Douglas Dieterich, MD</strong><br />Director, Institute for Liver Medicine</p><p>Professor of Medicine</p><p>Division of Liver Diseases</p><p>Mount Sinai School of Medicine</p><p>New York, New York</p><p><strong>Camilla S. Graham, MD, MPH</strong><br />Co-Director, Viral Hepatitis Clinic<br />Division of Infectious Diseases<br />Beth Israel Deaconess Medical Center<br />Harvard Medical School<br />Boston, Massachusetts</p><p><strong>Robert Wong, MD, MS </strong><br />Clinical Associate Professor<br />Division of Gastroenterology and Hepatology<br />Stanford University School of Medicine<br />Palo Alto, California</p><p>Link to full program:<br /><a href="https://bit.ly/3TuqFHI" target="_blank">https://bit.ly/3TuqFHI</a></p><p>Link to the slides: <br /><a href="https://bit.ly/4atS42z" target="_blank">https://bit.ly/4atS42z</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="26904801" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/0dc7fdb4-1baf-4f46-9a07-4c8f314eff3d/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=0dc7fdb4-1baf-4f46-9a07-4c8f314eff3d&amp;feed=OLtcmjL2"/>
      <itunes:title>How to Implement Earlier Hepatitis B and Hepatitis Delta Screening</itunes:title>
      <itunes:author>ProCE</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/78732e26-b7b2-41e9-8870-6b1aa8e938fe/3000x3000/proce-hbv-prp5673-pod775-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:27:52</itunes:duration>
      <itunes:summary>Listen as Douglas Dieterich, MD; Camilla S. Graham, MD, MPH; and Robert Wong, MD, MS, review barriers to and strategies for adopting new recommendations on universal HBV screening for all adults and best practices for screening of all patients with chronic HBV infection for HDV in the United States. </itunes:summary>
      <itunes:subtitle>Listen as Douglas Dieterich, MD; Camilla S. Graham, MD, MPH; and Robert Wong, MD, MS, review barriers to and strategies for adopting new recommendations on universal HBV screening for all adults and best practices for screening of all patients with chronic HBV infection for HDV in the United States. </itunes:subtitle>
      <itunes:keywords>screening, graham, hepatitis delta, viral hepatitis, testing, hhs, acip, wong, aasld, cdc, diagnosis, guideline-based screening, hepatitis b, hepatitis, hdv, hepatitis d, easl, hbv, implementation, vaccination, dieterich, guideline, hepatitis b virus</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>15</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">e3a9a25d-8138-4f5d-83d3-232aabdb11d3</guid>
      <title>CRE-ating Success: How I Use Rapid Diagnostic Tests to Manage Carbapenem-Resistant Enterobacterales Bacteremia</title>
      <description><![CDATA[<p>In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:</p><ul><li>Burden of CRE infections in the United States</li><li>Mechanisms of resistance</li><li>Changing epidemiology</li><li>Use of rapid diagnostic tests</li><li>IDSA guidance recommendations, including supporting data</li><li>Approach to designing treatment regimens, including weighing patient- and infection-related factors</li></ul><p><strong>Faculty:</strong></p><p><strong>Julie Ann Justo, PharmD, MS, FIDSA, BCPS</strong><br />Clinical Pharmacist Lead – Infectious Diseases<br />Inpatient Pharmacy<br />Dartmouth Hitchcock Medical Center<br />Lebanon, New Hampshire</p><p>Link to full program: <br /><a href="https://bit.ly/41a8Mj0" target="_blank">https://bit.ly/41a8Mj0</a></p><p>Link to accompanying ClinicalThought commentary:<br /><a href="https://bit.ly/4865T57" target="_blank">https://bit.ly/4865T57</a></p><p>Link to downloadable infographic: <br /><a href="https://bit.ly/3t7NpT2" target="_blank">https://bit.ly/3t7NpT2</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Thu, 7 Dec 2023 17:58:45 +0000</pubDate>
      <author>support@clinicaloptions.com (Julie Ann Justo PharmD MS FIDSA BCPS)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/cre-bacteremia-treatment-xB_HdC5C</link>
      <content:encoded><![CDATA[<p>In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:</p><ul><li>Burden of CRE infections in the United States</li><li>Mechanisms of resistance</li><li>Changing epidemiology</li><li>Use of rapid diagnostic tests</li><li>IDSA guidance recommendations, including supporting data</li><li>Approach to designing treatment regimens, including weighing patient- and infection-related factors</li></ul><p><strong>Faculty:</strong></p><p><strong>Julie Ann Justo, PharmD, MS, FIDSA, BCPS</strong><br />Clinical Pharmacist Lead – Infectious Diseases<br />Inpatient Pharmacy<br />Dartmouth Hitchcock Medical Center<br />Lebanon, New Hampshire</p><p>Link to full program: <br /><a href="https://bit.ly/41a8Mj0" target="_blank">https://bit.ly/41a8Mj0</a></p><p>Link to accompanying ClinicalThought commentary:<br /><a href="https://bit.ly/4865T57" target="_blank">https://bit.ly/4865T57</a></p><p>Link to downloadable infographic: <br /><a href="https://bit.ly/3t7NpT2" target="_blank">https://bit.ly/3t7NpT2</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="15313061" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/6de95dfc-7584-456b-9241-d87e9fb5cc14/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=6de95dfc-7584-456b-9241-d87e9fb5cc14&amp;feed=OLtcmjL2"/>
      <itunes:title>CRE-ating Success: How I Use Rapid Diagnostic Tests to Manage Carbapenem-Resistant Enterobacterales Bacteremia</itunes:title>
      <itunes:author>Julie Ann Justo PharmD MS FIDSA BCPS</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/d039419c-7530-440e-95b0-a2843a936937/3000x3000/proce-cre-bacteremia-prp5967-pod761-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:15:53</itunes:duration>
      <itunes:summary>Hear Julie Ann Justo, PharmD, MS, FIDSA, BCPS, share her approach to treating CRE infections through a patient case, including a review of the changing epidemiology of CRE, contributing mechanisms of resistance, and current IDSA guidance recommendations based on the latest data.</itunes:summary>
      <itunes:subtitle>Hear Julie Ann Justo, PharmD, MS, FIDSA, BCPS, share her approach to treating CRE infections through a patient case, including a review of the changing epidemiology of CRE, contributing mechanisms of resistance, and current IDSA guidance recommendations based on the latest data.</itunes:subtitle>
      <itunes:keywords>monotherapy, porin mutations, healthcare, oxa-48-like, apeks-np, esbl, optimal therapy, blood culture, idsa guidance, cre, ceftazidime/avibactam, antimicrobial stewardship, devices, antimicrobial resistance, combination therapy, aztreonam, death, epidemiology, ft&gt;mic, carbapenemase, hemodialysis, ndm, empiric therapy, julie justo, falcone, cdc, mechanisms of resistance, credible-cre, urinary tract infection, rapid diagnostic tests, cp-cre, turnaround times, genotypic testing, risk factors, travel, advocate, bacteremia, altered penicillin-binding proteins, non-carbapenemase-producing, hospital-onset disease, length of stay, endemic regions, cefiderocol, pk/pd, mechanical ventilation, drug exposure, imp, vim, mortality risk, prosthesis, invasive procedures, tigecycline, urgent threat, eravacycline, ampc, mbl, kpc</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>14</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">2456daa3-b911-4b3e-bfdf-b19f5f0a3fe2</guid>
      <title>Trailblazers: Pharmacist’s Role in Optimizing New RSV Vaccines for Older Adults</title>
      <description><![CDATA[<p>In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman provide practical strategies for implementing RSV vaccination into practice, including: </p><ul><li>Educating older adults on RSV vaccines </li><li>Providing effective, evidence-based recommendations</li><li>Shared decision-making </li><li>Identifying and addressing vaccine hesitancy </li><li>Proactive strategies in vaccinating for RSV </li><li>Predicting and overcoming barriers to RSV vaccination </li></ul><p><strong>Presenters:</strong></p><p><strong>Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP</strong><br />Clinical Professor<br />Ernest Mario School of Pharmacy<br />Rutgers, The State University of New Jersey<br />Piscataway, New Jersey<br />Internal Medicine Pharmacist<br />Robert Wood Johnson University Hospital<br />New Brunswick, New Jersey</p><p><strong>Christina M. Madison, PharmD, FCCP, AAHIVP</strong><br />Clinical Pharmacist<br />Founder and CEO, The Public Health Pharmacist, PLLC<br />Adjunct Associate Professor of Pharmacy Practice<br />Roseman University of Health Sciences<br />College of Pharmacy<br />Henderson, Nevada</p><p>Other program activities: </p><ul><li>Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role <br /><a href="https://bit.ly/49GUv1g" target="_blank">https://bit.ly/49GUv1g</a></li></ul><p>Link to CME: Claim Credit – <br /><a href="https://bit.ly/3uoY7VH" target="_blank">https://bit.ly/3uoY7VH</a></p><p>[After selecting the “Continue to Post Test” button:]</p><p>To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 27 Nov 2023 15:29:29 +0000</pubDate>
      <author>support@clinicaloptions.com (Mary Barna Bridgeman PharmD BCPS BCGP FASCP FCCP FNAP, Christina M Madison PharmD FCCP AAHIVP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/trailblazers-pharmacists-role-in-optimizing-new-rsv-vaccines-for-older-adults-xyHxow_O</link>
      <content:encoded><![CDATA[<p>In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman provide practical strategies for implementing RSV vaccination into practice, including: </p><ul><li>Educating older adults on RSV vaccines </li><li>Providing effective, evidence-based recommendations</li><li>Shared decision-making </li><li>Identifying and addressing vaccine hesitancy </li><li>Proactive strategies in vaccinating for RSV </li><li>Predicting and overcoming barriers to RSV vaccination </li></ul><p><strong>Presenters:</strong></p><p><strong>Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP</strong><br />Clinical Professor<br />Ernest Mario School of Pharmacy<br />Rutgers, The State University of New Jersey<br />Piscataway, New Jersey<br />Internal Medicine Pharmacist<br />Robert Wood Johnson University Hospital<br />New Brunswick, New Jersey</p><p><strong>Christina M. Madison, PharmD, FCCP, AAHIVP</strong><br />Clinical Pharmacist<br />Founder and CEO, The Public Health Pharmacist, PLLC<br />Adjunct Associate Professor of Pharmacy Practice<br />Roseman University of Health Sciences<br />College of Pharmacy<br />Henderson, Nevada</p><p>Other program activities: </p><ul><li>Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role <br /><a href="https://bit.ly/49GUv1g" target="_blank">https://bit.ly/49GUv1g</a></li></ul><p>Link to CME: Claim Credit – <br /><a href="https://bit.ly/3uoY7VH" target="_blank">https://bit.ly/3uoY7VH</a></p><p>[After selecting the “Continue to Post Test” button:]</p><p>To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="19007584" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/71d0402a-76f2-4bdb-8474-9717c8d12e27/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=71d0402a-76f2-4bdb-8474-9717c8d12e27&amp;feed=OLtcmjL2"/>
      <itunes:title>Trailblazers: Pharmacist’s Role in Optimizing New RSV Vaccines for Older Adults</itunes:title>
      <itunes:author>Mary Barna Bridgeman PharmD BCPS BCGP FASCP FCCP FNAP, Christina M Madison PharmD FCCP AAHIVP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/dc7c09c1-61de-489d-8f08-99d6a956a195/173f98b1-0516-4b36-b2e9-f80e3c9fc017/3000x3000/proce-rsv-updateds-prp6901-pod767-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:19:46</itunes:duration>
      <itunes:summary>Tune in to this podcast episode for expert pharmacist insights on proactively incorporating RSV vaccination strategies in your practice! Dr Christina Madison and Dr Mary Bridgeman provide practical guidance for educating patients, predicting and overcoming vaccination barriers, and the importance of shared decision-making.  </itunes:summary>
      <itunes:subtitle>Tune in to this podcast episode for expert pharmacist insights on proactively incorporating RSV vaccination strategies in your practice! Dr Christina Madison and Dr Mary Bridgeman provide practical guidance for educating patients, predicting and overcoming vaccination barriers, and the importance of shared decision-making.  </itunes:subtitle>
      <itunes:keywords>rsv in older adults, vaccine access, rsv vaccines, pharmacist vaccinations, pharmacist immunizations, vaccine hesitancy</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>12</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">f05e9db5-6d23-41db-a1ec-212e0fb271c8</guid>
      <title>Light on the Horizon: Developments in RSV Vaccines</title>
      <description><![CDATA[<p>In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman discuss the latest practical strategies for preventing RSV infection in older adults, including: </p><ul><li>Role of basic public health precautions</li><li>Available and emerging vaccines</li><li>Mechanisms of action, therapeutic targets, and pharmacology</li><li>Efficacy and safety data</li><li>FDA approval status and ACIP recommendations</li></ul><p><strong>Presenters:  </strong><br /><strong>Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP</strong><br />Clinical Professor<br />Ernest Mario School of Pharmacy<br />Rutgers, The State University of New Jersey<br />Piscataway, New Jersey<br />Internal Medicine Pharmacist<br />Robert Wood Johnson University Hospital<br />New Brunswick, New Jersey</p><p><strong>Christina M. Madison, PharmD, FCCP, AAHIVP  </strong><br />Clinical Pharmacist<br />Founder and CEO, The Public Health Pharmacist, PLLC<br />Adjunct Associate Professor of Pharmacy Practice<br />Roseman University of Health Sciences<br />College of Pharmacy<br />Henderson, Nevada</p><p>Other program activities:  </p><p>• <a href="https://proce.com/CE-CME-program/infectious-disease/rsv-prevention-for-older-adults/18079" target="_blank">Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role </a></p><p> </p><p> </p><p> </p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 21 Nov 2023 21:42:50 +0000</pubDate>
      <author>support@clinicaloptions.com (Christina M Madison PharmD FCCP AAHIVP, Mary Barna Bridgeman PharmD BCPS BCGP FASCP FCCP FNAP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/light-on-the-horizon-developments-in-rsv-vaccines-pamcgAyd</link>
      <content:encoded><![CDATA[<p>In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman discuss the latest practical strategies for preventing RSV infection in older adults, including: </p><ul><li>Role of basic public health precautions</li><li>Available and emerging vaccines</li><li>Mechanisms of action, therapeutic targets, and pharmacology</li><li>Efficacy and safety data</li><li>FDA approval status and ACIP recommendations</li></ul><p><strong>Presenters:  </strong><br /><strong>Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP</strong><br />Clinical Professor<br />Ernest Mario School of Pharmacy<br />Rutgers, The State University of New Jersey<br />Piscataway, New Jersey<br />Internal Medicine Pharmacist<br />Robert Wood Johnson University Hospital<br />New Brunswick, New Jersey</p><p><strong>Christina M. Madison, PharmD, FCCP, AAHIVP  </strong><br />Clinical Pharmacist<br />Founder and CEO, The Public Health Pharmacist, PLLC<br />Adjunct Associate Professor of Pharmacy Practice<br />Roseman University of Health Sciences<br />College of Pharmacy<br />Henderson, Nevada</p><p>Other program activities:  </p><p>• <a href="https://proce.com/CE-CME-program/infectious-disease/rsv-prevention-for-older-adults/18079" target="_blank">Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role </a></p><p> </p><p> </p><p> </p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="16142752" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/b54005da-e3a6-458e-9168-c56d79edba4d/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=b54005da-e3a6-458e-9168-c56d79edba4d&amp;feed=OLtcmjL2"/>
      <itunes:title>Light on the Horizon: Developments in RSV Vaccines</itunes:title>
      <itunes:author>Christina M Madison PharmD FCCP AAHIVP, Mary Barna Bridgeman PharmD BCPS BCGP FASCP FCCP FNAP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/dc7c09c1-61de-489d-8f08-99d6a956a195/c6c73ec0-2344-4864-8a02-47330e77762a/3000x3000/proce-rsv-updateds-prp6901-pod766-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:16:47</itunes:duration>
      <itunes:summary>Tune in to this podcast episode from Dr Christina Madison and Dr Mary Bridgeman to hear expert pharmacist insights on new and emerging RSV vaccines for older adults, including a review of the most recent clinical efficacy and safety data. </itunes:summary>
      <itunes:subtitle>Tune in to this podcast episode from Dr Christina Madison and Dr Mary Bridgeman to hear expert pharmacist insights on new and emerging RSV vaccines for older adults, including a review of the most recent clinical efficacy and safety data. </itunes:subtitle>
      <itunes:keywords>rsvpref, rsv in older adults, rsv vaccines, pharmacist vaccinations, pharmacist immunizations, rsvpref3, acip recommendations</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>13</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">ffdf58ba-3046-4669-9a46-243d247bf47f</guid>
      <title>Surveying the Landscape: Annual Burden of RSV in Older Adults</title>
      <description><![CDATA[<p>In this accredited podcast episode, Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP, discusses the most important things for pharmacists across all settings to know about RSV infections in patients 60 years of age or older, including: </p><ul><li>Incidence and prevalence of RSV in older adults, including hospitalization, mortality, epidemiology</li><li>Seasonality</li><li>Clinical manifestations</li><li>Risk factors for severe outcomes</li><li>Vulnerable groups and comorbidities</li></ul><p><strong>Presenter:</strong></p><p><strong>Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP</strong><br />Clinical Professor<br />Ernest Mario School of Pharmacy<br />Rutgers, The State University of New Jersey<br />Piscataway, New Jersey<br />Internal Medicine Pharmacist<br />Robert Wood Johnson University Hospital<br />New Brunswick, New Jersey</p><p>Other program activities: </p><ul><li>Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role <br /><a href="https://bit.ly/49GUv1g" target="_blank">https://bit.ly/49GUv1g</a></li></ul><p>Link to CME: Claim Credit – <a href="https://bit.ly/47GtNnK" target="_blank">https://bit.ly/47GtNnK</a><br />[After selecting the “Continue to Post Test” button:]</p><p>To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 21 Nov 2023 16:22:08 +0000</pubDate>
      <author>support@clinicaloptions.com (Mary Barna Bridgeman PharmD BCPS BCGP FASCP FCCP FNAP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/surveying-the-landscape-annual-burden-of-rsv-in-older-adults-rDMfYhmU</link>
      <content:encoded><![CDATA[<p>In this accredited podcast episode, Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP, discusses the most important things for pharmacists across all settings to know about RSV infections in patients 60 years of age or older, including: </p><ul><li>Incidence and prevalence of RSV in older adults, including hospitalization, mortality, epidemiology</li><li>Seasonality</li><li>Clinical manifestations</li><li>Risk factors for severe outcomes</li><li>Vulnerable groups and comorbidities</li></ul><p><strong>Presenter:</strong></p><p><strong>Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP</strong><br />Clinical Professor<br />Ernest Mario School of Pharmacy<br />Rutgers, The State University of New Jersey<br />Piscataway, New Jersey<br />Internal Medicine Pharmacist<br />Robert Wood Johnson University Hospital<br />New Brunswick, New Jersey</p><p>Other program activities: </p><ul><li>Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role <br /><a href="https://bit.ly/49GUv1g" target="_blank">https://bit.ly/49GUv1g</a></li></ul><p>Link to CME: Claim Credit – <a href="https://bit.ly/47GtNnK" target="_blank">https://bit.ly/47GtNnK</a><br />[After selecting the “Continue to Post Test” button:]</p><p>To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="12380836" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/5f0e3f56-5462-4187-9343-cd003acb8e9f/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=5f0e3f56-5462-4187-9343-cd003acb8e9f&amp;feed=OLtcmjL2"/>
      <itunes:title>Surveying the Landscape: Annual Burden of RSV in Older Adults</itunes:title>
      <itunes:author>Mary Barna Bridgeman PharmD BCPS BCGP FASCP FCCP FNAP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/dc7c09c1-61de-489d-8f08-99d6a956a195/61a11fbf-9a44-4763-87ad-7300b3a503c8/3000x3000/proce-rsv-updateds-prp6901-pod765-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:12:52</itunes:duration>
      <itunes:summary>Tune in to this podcast from Dr Mary Bridgeman for expert pharmacist insights on the burden of RSV on older adults, including clinical manifestations, recognizing those most at risk, and protecting vulnerable patients. </itunes:summary>
      <itunes:subtitle>Tune in to this podcast from Dr Mary Bridgeman for expert pharmacist insights on the burden of RSV on older adults, including clinical manifestations, recognizing those most at risk, and protecting vulnerable patients. </itunes:subtitle>
      <itunes:keywords>rsv in older adults, rsv vaccines, burden of rsv, pharmacist vaccinations, pharmacist immunizations, risk factors for rsv</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>11</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">14a90299-8870-4b0d-a2fd-7d2e2205771f</guid>
      <title>Our Experiences With the Latest Treatment Options in Ovarian Cancer: The Pharmacist Perspective</title>
      <description><![CDATA[<p>In this episode, Sarah Hayward, PharmD, BCOP, and Amy Ly Indorf, PharmD, BCOP, discuss their experiences providing care for patients with advanced ovarian cancer, with topics including:</p><ul><li>PARP inhibitors as frontline maintenance therapy</li><li>Patient education and counseling on PARP inhibitors</li><li>Helping patients access newer therapies</li><li>Experiences with mirvetuximab soravtansine</li><li>Patient education and counseling on mirvetuximab soravtansine</li><li>Treatment modalities on the horizon </li></ul><p><br /><strong>Presenters</strong>:</p><p>Sarah Hayward, PharmD, BCOP<br />Clinical Pharmacy Specialist,<br />Gynecologic Oncology<br />Stephenson Cancer Center at<br />OU Health<br />Oklahoma City, Oklahoma</p><p>Amy Ly Indorf, PharmD, BCOP<br />Clinical Assistant Professor<br />University of Washington <br />School of Pharmacy<br />Clinical Oncology Pharmacist<br />UW Medicine<br />Fred Hutchinson Cancer Center<br />Seattle, Washington</p><p>Supported by educational grants from GSK and Novocure, Inc.</p><p>Link to full program:<br /><a href="https://bit.ly/44fUiOU" target="_blank">https://bit.ly/44fUiOU</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 28 Jun 2023 13:28:01 +0000</pubDate>
      <author>support@clinicaloptions.com (Sarah Hawyard PharmD BCOP, Amy Ly Indorf PharmD BCOP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/pharmacist-perspective-oc-mwL7L8vJ</link>
      <content:encoded><![CDATA[<p>In this episode, Sarah Hayward, PharmD, BCOP, and Amy Ly Indorf, PharmD, BCOP, discuss their experiences providing care for patients with advanced ovarian cancer, with topics including:</p><ul><li>PARP inhibitors as frontline maintenance therapy</li><li>Patient education and counseling on PARP inhibitors</li><li>Helping patients access newer therapies</li><li>Experiences with mirvetuximab soravtansine</li><li>Patient education and counseling on mirvetuximab soravtansine</li><li>Treatment modalities on the horizon </li></ul><p><br /><strong>Presenters</strong>:</p><p>Sarah Hayward, PharmD, BCOP<br />Clinical Pharmacy Specialist,<br />Gynecologic Oncology<br />Stephenson Cancer Center at<br />OU Health<br />Oklahoma City, Oklahoma</p><p>Amy Ly Indorf, PharmD, BCOP<br />Clinical Assistant Professor<br />University of Washington <br />School of Pharmacy<br />Clinical Oncology Pharmacist<br />UW Medicine<br />Fred Hutchinson Cancer Center<br />Seattle, Washington</p><p>Supported by educational grants from GSK and Novocure, Inc.</p><p>Link to full program:<br /><a href="https://bit.ly/44fUiOU" target="_blank">https://bit.ly/44fUiOU</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="14599418" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/ad81f81f-9b4b-4faa-b892-6f87c47cba3e/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=ad81f81f-9b4b-4faa-b892-6f87c47cba3e&amp;feed=OLtcmjL2"/>
      <itunes:title>Our Experiences With the Latest Treatment Options in Ovarian Cancer: The Pharmacist Perspective</itunes:title>
      <itunes:author>Sarah Hawyard PharmD BCOP, Amy Ly Indorf PharmD BCOP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/825f18b8-323b-4f15-b2f7-3918609398f0/3000x3000/ovarian-cancer-hopa-prp5760-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:15:08</itunes:duration>
      <itunes:summary>Experts discuss their experiences with providing patient education on PARP inhibitors and mirvetuximab soravtansine and a potentially emerging treatment modality in advanced ovarian cancer.</itunes:summary>
      <itunes:subtitle>Experts discuss their experiences with providing patient education on PARP inhibitors and mirvetuximab soravtansine and a potentially emerging treatment modality in advanced ovarian cancer.</itunes:subtitle>
      <itunes:keywords>parp inhibitors, mirvetuximab soravtansine, tumor treating fields, niraparib, rucaparib, olaparib, patient access, frontline maintenance, specialty pharmacy</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>10</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">1c5de371-2467-486f-8930-ef9b9cfcfeed</guid>
      <title>2023 Audio Recap: Principles of Outpatient COVID-19 Management</title>
      <description><![CDATA[<p>In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:</p><ul><li>Current COVID-19 landscape</li><li>Rapid antigen tests and PCR tests</li><li>Risk stratification of patients who have a positive SARS-CoV-2 test</li><li>Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)</li><li>Long COVID</li></ul><p>Presenters:<br /><strong>Renslow Sherer, MD</strong><br />Director, International HIV Training Center<br />Professor of Medicine<br />Section of Infectious Diseases and Global Health<br />Department of Medicine<br />University of Chicago<br />Chicago, Illinois</p><p><strong>Trinh P. Vu, PharmD, BCIDP</strong><br />Clinical Pharmacy Specialist in Infectious Diseases<br />Department of Pharmaceutical Services<br />Emory University Hospital Midtown<br />Atlanta, Georgia</p><p>To download the slides: <a href="https://clinicaloptions.com/CE-CME/infectious-disease/slides:-outpatient-covid-19/100004742" target="_blank">bit.ly/3oHKC09</a></p><p>To view the full online program: <a href="https://clinicaloptions.com/CE-CME-program/infectious-disease/covid-19-early-outpatient-management/100002555" target="_blank">bit.ly/4201xcO</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 3 May 2023 16:46:54 +0000</pubDate>
      <author>support@clinicaloptions.com (Renslow Sherer MD, Trinh P. Vu PharmD BCIDP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/2023-audio-recap-principles-of-outpatient-covid-19-management-9wbVHsAR</link>
      <content:encoded><![CDATA[<p>In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:</p><ul><li>Current COVID-19 landscape</li><li>Rapid antigen tests and PCR tests</li><li>Risk stratification of patients who have a positive SARS-CoV-2 test</li><li>Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)</li><li>Long COVID</li></ul><p>Presenters:<br /><strong>Renslow Sherer, MD</strong><br />Director, International HIV Training Center<br />Professor of Medicine<br />Section of Infectious Diseases and Global Health<br />Department of Medicine<br />University of Chicago<br />Chicago, Illinois</p><p><strong>Trinh P. Vu, PharmD, BCIDP</strong><br />Clinical Pharmacy Specialist in Infectious Diseases<br />Department of Pharmaceutical Services<br />Emory University Hospital Midtown<br />Atlanta, Georgia</p><p>To download the slides: <a href="https://clinicaloptions.com/CE-CME/infectious-disease/slides:-outpatient-covid-19/100004742" target="_blank">bit.ly/3oHKC09</a></p><p>To view the full online program: <a href="https://clinicaloptions.com/CE-CME-program/infectious-disease/covid-19-early-outpatient-management/100002555" target="_blank">bit.ly/4201xcO</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="71793750" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/0559e864-4bf8-4f47-b264-99266471b7ec/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=0559e864-4bf8-4f47-b264-99266471b7ec&amp;feed=OLtcmjL2"/>
      <itunes:title>2023 Audio Recap: Principles of Outpatient COVID-19 Management</itunes:title>
      <itunes:author>Renslow Sherer MD, Trinh P. Vu PharmD BCIDP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/475a8673-2011-4cf7-ae34-80b3617ecd7e/b52aea37-ef9f-48c8-b64d-0fd2d270fa07/3000x3000/pod562-c19-early-outpatient-podcast3-proce-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>01:14:42</itunes:duration>
      <itunes:summary>Listen to Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss updated information regarding outpatient management of COVID-19, including testing, risk stratification, treatment guidelines, treatment selection, and long COVID.</itunes:summary>
      <itunes:subtitle>Listen to Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss updated information regarding outpatient management of COVID-19, including testing, risk stratification, treatment guidelines, treatment selection, and long COVID.</itunes:subtitle>
      <itunes:keywords>remdesivir, pcr test, vaccination status, antivirals, high risk, ritonavir, covid-19 testing, ambulatory covid-19, nirmatrelvir plus ritonavir, long covid, nih, epic-hr, post-acute sequelae of covid-19, pasc, paxlovid, immunocompromise, comorbidities, rapid antigen test, molnupiravir, pcr, idsa guidelines, veklury, outpatient, covid-19 outpatient management, covid-19 ambulatory management, ambulatory, nirmatrelvir + ritonavir, omicron transmissibility, idsa, pinetree, nih guidelines, standard risk, risk stratification, unvaccinated, covid-19, rat, vaccine booster, bivalent booster, transmissibility, covid, omicron, nirmatrelvir, lagevrio, fully vaccinated, antiviral, polymerase chain reaction, guidelines, sars-cov-2, outpatient covid-19, move-out, age, covid-19 management, immunocompromised</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>9</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">a30f895a-50c9-4d4c-8522-75c02dfb25cf</guid>
      <title>GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes</title>
      <description><![CDATA[<p>In this episode, pharmacists Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM, and Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, discuss the use of GLP-1 receptor agonists in patients with type 2 diabetes and provide answers to commonly asked questions. Listen to their conversation about the differences between short-acting vs long-acting agents; the benefits of use in combination with other medications, such as SGLT2 inhibitors, DPP-4 inhibitors, and metformin; their benefits in heart failure; and their role in the updated consensus statement from the American Diabetes Association/European Association for the Study of Diabetes. </p><p><strong>Presenters:</strong></p><p><strong>Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM</strong><br /><i>Clinical Professor</i><br />Department of Pharmacy Practice<br />Auburn University Harrison College of Pharmacy<br /><i>Clinical Pharmacist</i><br />Baptist Health Foundation Center for Medical and Surgical Care<br />Princeton Baptist Medical Center/Brookwood Baptist Health<br />Birmingham, Alabama</p><p><strong>Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP</strong><br /><i>Professor</i><br />Department of Pharmacy Practice<br />Midwestern University<br />College of Pharmacy<br />Downers Grove, Illinois<br /><i>Clinical Pharmacist</i><br />Advocate Medical Group<br />Chicago, Illinois</p><p>Content based on an online CE program supported by an educational grant from Novo Nordisk, Inc.</p><p>Link to full program: <br /><a href="https://bit.ly/3Un1xQi" target="_blank">https://bit.ly/3Un1xQi</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 4 Nov 2022 20:30:00 +0000</pubDate>
      <author>support@clinicaloptions.com (Kristi Kelley PharmD FCCP BCPS BCACP CDCES BC-ADM, Christie Schumacher PharmD BCPS BCACP BCCP BC-ADM CDCES FCCP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/glp-1-ras-in-t2d-fmalzHFO</link>
      <content:encoded><![CDATA[<p>In this episode, pharmacists Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM, and Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, discuss the use of GLP-1 receptor agonists in patients with type 2 diabetes and provide answers to commonly asked questions. Listen to their conversation about the differences between short-acting vs long-acting agents; the benefits of use in combination with other medications, such as SGLT2 inhibitors, DPP-4 inhibitors, and metformin; their benefits in heart failure; and their role in the updated consensus statement from the American Diabetes Association/European Association for the Study of Diabetes. </p><p><strong>Presenters:</strong></p><p><strong>Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM</strong><br /><i>Clinical Professor</i><br />Department of Pharmacy Practice<br />Auburn University Harrison College of Pharmacy<br /><i>Clinical Pharmacist</i><br />Baptist Health Foundation Center for Medical and Surgical Care<br />Princeton Baptist Medical Center/Brookwood Baptist Health<br />Birmingham, Alabama</p><p><strong>Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP</strong><br /><i>Professor</i><br />Department of Pharmacy Practice<br />Midwestern University<br />College of Pharmacy<br />Downers Grove, Illinois<br /><i>Clinical Pharmacist</i><br />Advocate Medical Group<br />Chicago, Illinois</p><p>Content based on an online CE program supported by an educational grant from Novo Nordisk, Inc.</p><p>Link to full program: <br /><a href="https://bit.ly/3Un1xQi" target="_blank">https://bit.ly/3Un1xQi</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="21727470" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/14dfdc15-1624-4a49-877d-0a710135a74d/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=14dfdc15-1624-4a49-877d-0a710135a74d&amp;feed=OLtcmjL2"/>
      <itunes:title>GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes</itunes:title>
      <itunes:author>Kristi Kelley PharmD FCCP BCPS BCACP CDCES BC-ADM, Christie Schumacher PharmD BCPS BCACP BCCP BC-ADM CDCES FCCP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/1694d1a5-4dc4-42fa-bc9d-4af54bc4e256/3000x3000/proce-podcast-glp-1-ras-in-t2d-icon.jpg?aid=rss_feed"/>
      <itunes:duration>00:22:34</itunes:duration>
      <itunes:summary>In this episode, pharmacists Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM, and Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, discuss the use of GLP-1 receptor agonists in patients with type 2 diabetes and provide answers to commonly asked questions. Listen to their conversation about the differences between short-acting vs long-acting agents; the benefits of use in combination with other medications, such as SGLT2 inhibitors, DPP-4 inhibitors, and metformin; their benefits in heart failure; and their role in the updated consensus statement from the American Diabetes Association/European Association for the Study of Diabetes.</itunes:summary>
      <itunes:subtitle>In this episode, pharmacists Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM, and Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, discuss the use of GLP-1 receptor agonists in patients with type 2 diabetes and provide answers to commonly asked questions. Listen to their conversation about the differences between short-acting vs long-acting agents; the benefits of use in combination with other medications, such as SGLT2 inhibitors, DPP-4 inhibitors, and metformin; their benefits in heart failure; and their role in the updated consensus statement from the American Diabetes Association/European Association for the Study of Diabetes.</itunes:subtitle>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>8</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">485abf7d-6c75-47db-b28b-168b86d6b8c4</guid>
      <title>Pearls on the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in CKD in T2D</title>
      <description><![CDATA[<p>In this episode, Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, discuss the use of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes, including:</p><ul><li>Overview of chronic kidney disease</li><li>Guideline recommendations</li><li>Evidence for finerenone</li><li>Role of the pharmacist</li></ul><p>Presenter:</p><p><strong>Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP</strong><br /><i>Endocrine Clinical Pharmacy Specialist</i><br /><i>CGM and Remote Monitoring Program Coordinator</i><br />Endocrinology and Metabolism Institute<br />Cleveland Clinic<br />Cleveland, Ohio</p><p><strong>Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP</strong><br /><i>Vice Chair and Allen I. White Distinguished Professor</i><br />Department of Pharmacotherapy<br />College of Pharmacy and Pharmaceutical Sciences  <br />Washington State University<br />Spokane, Washington</p><p>Review the downloadable slideset and the full program at:<br /><a href="https://bit.ly/3wxNAod" target="_blank">https://bit.ly/3wxNAod</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 17 May 2022 20:30:00 +0000</pubDate>
      <author>support@clinicaloptions.com (Diana Isaacs PharmD BCPS BCACP CDCES BC-ADM FADCES FCCP, Joshua J. Neumiller PharmD CDCES FADCES FASCP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/pearls-on-mras-for-t2d-in-ckd-nw44XPN4</link>
      <content:encoded><![CDATA[<p>In this episode, Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, discuss the use of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes, including:</p><ul><li>Overview of chronic kidney disease</li><li>Guideline recommendations</li><li>Evidence for finerenone</li><li>Role of the pharmacist</li></ul><p>Presenter:</p><p><strong>Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP</strong><br /><i>Endocrine Clinical Pharmacy Specialist</i><br /><i>CGM and Remote Monitoring Program Coordinator</i><br />Endocrinology and Metabolism Institute<br />Cleveland Clinic<br />Cleveland, Ohio</p><p><strong>Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP</strong><br /><i>Vice Chair and Allen I. White Distinguished Professor</i><br />Department of Pharmacotherapy<br />College of Pharmacy and Pharmaceutical Sciences  <br />Washington State University<br />Spokane, Washington</p><p>Review the downloadable slideset and the full program at:<br /><a href="https://bit.ly/3wxNAod" target="_blank">https://bit.ly/3wxNAod</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="28121630" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/b4b28df3-15c8-4c13-96a8-fdde6810325a/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=b4b28df3-15c8-4c13-96a8-fdde6810325a&amp;feed=OLtcmjL2"/>
      <itunes:title>Pearls on the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in CKD in T2D</itunes:title>
      <itunes:author>Diana Isaacs PharmD BCPS BCACP CDCES BC-ADM FADCES FCCP, Joshua J. Neumiller PharmD CDCES FADCES FASCP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/5f4209c7-304e-42e2-bddf-d79c8377f51d/3000x3000/pod409-ckd-in-t2dm-apha-podcast-icon.jpg?aid=rss_feed"/>
      <itunes:duration>00:29:14</itunes:duration>
      <itunes:summary>Drs Diana Isaacs and Joshua J. Neumiller summarize key information on the evidence behind the use of finerenone in diabetic kidney disease, selecting appropriate patients for finerenone therapy, and the role of the pharmacist in caring for these patients.</itunes:summary>
      <itunes:subtitle>Drs Diana Isaacs and Joshua J. Neumiller summarize key information on the evidence behind the use of finerenone in diabetic kidney disease, selecting appropriate patients for finerenone therapy, and the role of the pharmacist in caring for these patients.</itunes:subtitle>
      <itunes:keywords>mineralocorticoid receptor antagonist, ckd, dkd, mra, sglt2 inhibitors, chronic kidney disease, diana isaacs, joshua neumiller, type 2 diabetes, diabetic kidney disease, finerenone, arb, ace inhibitor</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>7</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">cc30d338-84ce-4d26-840b-228e402f32a8</guid>
      <title>Cardiology Pharmacist’s Insights on Patient Engagement, Healthcare Provider Collaboration, and Reducing Disparities</title>
      <description><![CDATA[<p>This podcast is the third in a series of three featuring insights from expert cardiology pharmacists on nonvalvular atrial fibrillation (NVAF). In this episode, pharmacist Kathleen A. Lusk, PharmD, BCPS, BCCP, provides an overview of health disparities, patient engagement, and collaborative team-based care to optimize outcomes for patients with NVAF. Dr Lusk reviews best practices in using the principles of motivational interviewing to employ shared decision-making and models these strategies with 2 simulated clinical patient visits. Common barriers, such as medication access and adherence, also are discussed, along with practical solutions for overcoming these care obstacles. </p><p>Presenter:</p><p><strong>Kathleen A. Lusk, PharmD, BCPS, BCCP</strong><br /><i>Associate Professor and Vice Chair</i><br />Department of Pharmacy Practice<br />University of the Incarnate Word Feik School of Pharmacy <br /><i>Adjunct Assistant Professor</i><br /><i>Clinical Pharmacy Specialist</i><br />Division of Cardiology<br />Department of Medicine<br />UT Health San Antonio<br />San Antonio, Texas</p><p>Content is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance.</p><p>This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to:<br /><a href="https://bit.ly/3OMazV8" target="_blank">https://bit.ly/3OMazV8</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 26 Apr 2022 19:00:00 +0000</pubDate>
      <author>support@clinicaloptions.com (Kathleen A Lusk PharmD BCPS BCCP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/patient-engagement-HT_1k_cU</link>
      <content:encoded><![CDATA[<p>This podcast is the third in a series of three featuring insights from expert cardiology pharmacists on nonvalvular atrial fibrillation (NVAF). In this episode, pharmacist Kathleen A. Lusk, PharmD, BCPS, BCCP, provides an overview of health disparities, patient engagement, and collaborative team-based care to optimize outcomes for patients with NVAF. Dr Lusk reviews best practices in using the principles of motivational interviewing to employ shared decision-making and models these strategies with 2 simulated clinical patient visits. Common barriers, such as medication access and adherence, also are discussed, along with practical solutions for overcoming these care obstacles. </p><p>Presenter:</p><p><strong>Kathleen A. Lusk, PharmD, BCPS, BCCP</strong><br /><i>Associate Professor and Vice Chair</i><br />Department of Pharmacy Practice<br />University of the Incarnate Word Feik School of Pharmacy <br /><i>Adjunct Assistant Professor</i><br /><i>Clinical Pharmacy Specialist</i><br />Division of Cardiology<br />Department of Medicine<br />UT Health San Antonio<br />San Antonio, Texas</p><p>Content is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance.</p><p>This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to:<br /><a href="https://bit.ly/3OMazV8" target="_blank">https://bit.ly/3OMazV8</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="29690081" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/6010c455-a028-4df7-87e5-ed064bed7d06/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=6010c455-a028-4df7-87e5-ed064bed7d06&amp;feed=OLtcmjL2"/>
      <itunes:title>Cardiology Pharmacist’s Insights on Patient Engagement, Healthcare Provider Collaboration, and Reducing Disparities</itunes:title>
      <itunes:author>Kathleen A Lusk PharmD BCPS BCCP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/b1eb8cec-19af-44d3-850a-70af434c86e8/3000x3000/pod497-undiagnosed-nvaf-podcast-icon-3.jpg?aid=rss_feed"/>
      <itunes:duration>00:30:50</itunes:duration>
      <itunes:summary>In this podcast, expert cardiology pharmacist Dr Kathleen Lusk provides insights on best practices for engaging patients and the healthcare team in collaborative, shared decision-making for management of NVAF.</itunes:summary>
      <itunes:subtitle>In this podcast, expert cardiology pharmacist Dr Kathleen Lusk provides insights on best practices for engaging patients and the healthcare team in collaborative, shared decision-making for management of NVAF.</itunes:subtitle>
      <itunes:keywords>medication assistance, nonvalvular atrial fibrillation, collaborative care, medication access, clinical pharmacy, kathleen lusk pharmd, standardized patient, cardiology, motivational interviewing, patient engagement, pharmacy practice, health disparities, health literacy, nvaf, medication adherence, interdisciplinary team, shared decision-making</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>6</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">bc7e08f9-98fe-4e4b-9df7-488b09a24300</guid>
      <title>Cardiology Pharmacists’ Insights on Recognizing the Burden of NVAF and Role of Screening in Pharmacy Settings</title>
      <description><![CDATA[<p>This podcast is the first in a series of three featuring cardiology pharmacists Kathleen A. Lusk, PharmD, BCPS, BCCP, and Stephanie Dwyer Kaluzna, PharmD, BCCP. In this episode, Drs Lusk and Dwyer Kaluzna provide an overview of nonvalvular atrial fibrillation (NVAF), including prevalence, burden, and consequences of undiagnosed NVAF and the role of pharmacists in screening for the condition in various pharmacy settings.</p><p>Presenters:</p><p><strong>Kathleen A. Lusk, PharmD, BCPS, BCCP  </strong><br /><i>Associate Professor and Vice Chair  </i><br />Department of Pharmacy Practice<br />University of the Incarnate Word Feik School of Pharmacy  <br /><i>Adjunct Assistant Professor</i><br /><i>Clinical Pharmacy Specialist</i><br />Division of Cardiology<br />Department of Medicine<br />UT Health San Antonio<br />San Antonio, Texas</p><p><strong>Stephanie Dwyer Kaluzna, PharmD, BCCP  </strong><br /><i>Clinical Assistant Professor</i><br />Department of Pharmacy Practice<br />University of Illinois Chicago College of Pharmacy<br /><i>Cardiovascular Clinical Pharmacist</i><br />University of Illinois Hospital and Health Science System<br />Chicago, Illinois</p><p>Content is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance.</p><p>This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to<br /><a href="https://bit.ly/3OMazV8" target="_blank">https://bit.ly/3OMazV8</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 25 Apr 2022 21:00:00 +0000</pubDate>
      <author>support@clinicaloptions.com (Kathleen A. Lusk PharmD BCPS BCCP, Stephanie Dwyer Kaluzna PharmD BCCP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/nvaf-burden-and-screening-unB2GVWu</link>
      <content:encoded><![CDATA[<p>This podcast is the first in a series of three featuring cardiology pharmacists Kathleen A. Lusk, PharmD, BCPS, BCCP, and Stephanie Dwyer Kaluzna, PharmD, BCCP. In this episode, Drs Lusk and Dwyer Kaluzna provide an overview of nonvalvular atrial fibrillation (NVAF), including prevalence, burden, and consequences of undiagnosed NVAF and the role of pharmacists in screening for the condition in various pharmacy settings.</p><p>Presenters:</p><p><strong>Kathleen A. Lusk, PharmD, BCPS, BCCP  </strong><br /><i>Associate Professor and Vice Chair  </i><br />Department of Pharmacy Practice<br />University of the Incarnate Word Feik School of Pharmacy  <br /><i>Adjunct Assistant Professor</i><br /><i>Clinical Pharmacy Specialist</i><br />Division of Cardiology<br />Department of Medicine<br />UT Health San Antonio<br />San Antonio, Texas</p><p><strong>Stephanie Dwyer Kaluzna, PharmD, BCCP  </strong><br /><i>Clinical Assistant Professor</i><br />Department of Pharmacy Practice<br />University of Illinois Chicago College of Pharmacy<br /><i>Cardiovascular Clinical Pharmacist</i><br />University of Illinois Hospital and Health Science System<br />Chicago, Illinois</p><p>Content is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance.</p><p>This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to<br /><a href="https://bit.ly/3OMazV8" target="_blank">https://bit.ly/3OMazV8</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="29173901" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/d3b180a3-2628-45c9-8646-1b05d798c513/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=d3b180a3-2628-45c9-8646-1b05d798c513&amp;feed=OLtcmjL2"/>
      <itunes:title>Cardiology Pharmacists’ Insights on Recognizing the Burden of NVAF and Role of Screening in Pharmacy Settings</itunes:title>
      <itunes:author>Kathleen A. Lusk PharmD BCPS BCCP, Stephanie Dwyer Kaluzna PharmD BCCP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/a05edac9-a993-4279-876c-6bd8d0067e2e/3000x3000/pod384-undiagnosed-nvaf-podcast-icon-1.jpg?aid=rss_feed"/>
      <itunes:duration>00:30:17</itunes:duration>
      <itunes:summary>In this podcast, expert cardiology pharmacists Dr Kathleen Lusk and Dr Stephanie Dwyer Kaluzna discuss the prevalence, burden, and consequences of undiagnosed NVAF. They will explore evidence-based methods for NVAF screening and provide strategies to incorporate these within various pharmacy settings.</itunes:summary>
      <itunes:subtitle>In this podcast, expert cardiology pharmacists Dr Kathleen Lusk and Dr Stephanie Dwyer Kaluzna discuss the prevalence, burden, and consequences of undiagnosed NVAF. They will explore evidence-based methods for NVAF screening and provide strategies to incorporate these within various pharmacy settings.</itunes:subtitle>
      <itunes:keywords>screening, nonvalvular atrial fibrillation, clinical pharmacy, kathleen lusk pharmd, cardiology, pharmacy practice, stephanie dwyer kaluzna pharmd, nvaf</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>4</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">e207392c-36a4-4966-8572-b9f65c09a87f</guid>
      <title>Cardiology Pharmacist’s Insights on Stroke Prevention in NVAF With Evidence-Based DOAC Therapy</title>
      <description><![CDATA[<p>This podcast is the second in a series of three featuring insights from expert cardiology pharmacists on nonvalvular atrial fibrillation (NVAF). In this episode, cardiology pharmacist Stephanie Dwyer Kaluzna, PharmD, BCCP, reviews key literature and guideline recommendations for stroke prevention in patients with NVAF. Dr Dwyer Kaluzna discusses the most recent evidence for prescribing, dosing, and monitoring direct oral anticoagulants (DOACs); using the risk-screening tools HAS-BLED and CHA2DS2-VASc to design patient-specific pharmacotherapy plans; and the use of DOACs in special patient populations, including older patients, patients with end-stage renal disease, and patients with low or high body weights.</p><p>Presenter:</p><p><strong>Stephanie Dwyer Kaluzna, PharmD, BCCP  </strong><br />Clinical Assistant Professor<br />Department of Pharmacy Practice<br />University of Illinois Chicago College of Pharmacy<br />Cardiovascular Clinical Pharmacist<br />University of Illinois Hospital and Health Science System<br />Chicago, Illinois</p><p>Content is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance.</p><p>This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to<br /><a href="https://bit.ly/3OMazV8" target="_blank">https://bit.ly/3OMazV8</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 25 Apr 2022 21:00:00 +0000</pubDate>
      <author>support@clinicaloptions.com (Stephanie Dwyer Kaluzna PharmD BCCP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/stroke-prevention-with-doacs-GDbk8GUg</link>
      <content:encoded><![CDATA[<p>This podcast is the second in a series of three featuring insights from expert cardiology pharmacists on nonvalvular atrial fibrillation (NVAF). In this episode, cardiology pharmacist Stephanie Dwyer Kaluzna, PharmD, BCCP, reviews key literature and guideline recommendations for stroke prevention in patients with NVAF. Dr Dwyer Kaluzna discusses the most recent evidence for prescribing, dosing, and monitoring direct oral anticoagulants (DOACs); using the risk-screening tools HAS-BLED and CHA2DS2-VASc to design patient-specific pharmacotherapy plans; and the use of DOACs in special patient populations, including older patients, patients with end-stage renal disease, and patients with low or high body weights.</p><p>Presenter:</p><p><strong>Stephanie Dwyer Kaluzna, PharmD, BCCP  </strong><br />Clinical Assistant Professor<br />Department of Pharmacy Practice<br />University of Illinois Chicago College of Pharmacy<br />Cardiovascular Clinical Pharmacist<br />University of Illinois Hospital and Health Science System<br />Chicago, Illinois</p><p>Content is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance.</p><p>This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to<br /><a href="https://bit.ly/3OMazV8" target="_blank">https://bit.ly/3OMazV8</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="27471561" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/ed7ce7e2-6bab-447f-9c90-f2631df938c9/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=ed7ce7e2-6bab-447f-9c90-f2631df938c9&amp;feed=OLtcmjL2"/>
      <itunes:title>Cardiology Pharmacist’s Insights on Stroke Prevention in NVAF With Evidence-Based DOAC Therapy</itunes:title>
      <itunes:author>Stephanie Dwyer Kaluzna PharmD BCCP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/47e48744-737b-41e9-947a-c5cce271e00d/3000x3000/pod496-undiagnosed-nvaf-podcast-icon-2.jpg?aid=rss_feed"/>
      <itunes:duration>00:28:29</itunes:duration>
      <itunes:summary>In this podcast, expert cardiology pharmacist Dr Stephanie Dwyer Kaluzna discusses evidence-based recommendations on the use of DOAC therapy in NVAF for stroke prevention.</itunes:summary>
      <itunes:subtitle>In this podcast, expert cardiology pharmacist Dr Stephanie Dwyer Kaluzna discusses evidence-based recommendations on the use of DOAC therapy in NVAF for stroke prevention.</itunes:subtitle>
      <itunes:keywords>anticoagulation, nonvalvular atrial fibrillation, stroke prevention, cardioembolic stroke, clinical pharmacy, doac, direct oral anticoagulant, cardiology, pharmacy practice, stephanie dwyer kaluzna pharmd, nvaf</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>5</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">75b6f586-8836-4eee-ae3f-77035827694a</guid>
      <title>Best Practices for Pharmacists to Optimize Use of Obesity Treatment Options and Overcome Barriers to Care</title>
      <description><![CDATA[<p>In this episode, pharmacists Megan Adelman, PharmD, BCPS, BCGP, CDCES, and Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA, provide an overview of obesity, including pathophysiology and the benefits of long-term weight loss, and discuss guideline recommendations for treatment, pharmacotherapy options including injectable agents, and overcoming barriers to care.</p><p>Presenters:</p><p><strong>Megan Adelman, PharmD, BCPS, BCGP, CDCES</strong><br /><i>Family Medicine Clinical Specialist</i><br />Center for Family Medicine<br />Cleveland Clinic Akron General<br />Akron, Ohio</p><p><strong>Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA</strong><br /><i>Professor</i><br />Department of Pharmacy Practice<br />College of Pharmacy-Glendale<br />Midwestern University<br />Glendale, Arizona</p><p>Content based on an online CE program supported by an educational grant from Novo Nordisk, Inc.</p><p>Link to full program:<br /><a href="https://bit.ly/3EAARVu" target="_blank">https://bit.ly/3EAARVu</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 22 Apr 2022 19:00:00 +0000</pubDate>
      <author>support@clinicaloptions.com (Megan Adelman PharmD BCPS BCGP CDCES, Elizabeth Pogge PharmD MPH BCPS-AQ Cardiology BCGP FASCP FAzPA)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/best-practices-for-obesity-treatment-gwxjouox</link>
      <content:encoded><![CDATA[<p>In this episode, pharmacists Megan Adelman, PharmD, BCPS, BCGP, CDCES, and Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA, provide an overview of obesity, including pathophysiology and the benefits of long-term weight loss, and discuss guideline recommendations for treatment, pharmacotherapy options including injectable agents, and overcoming barriers to care.</p><p>Presenters:</p><p><strong>Megan Adelman, PharmD, BCPS, BCGP, CDCES</strong><br /><i>Family Medicine Clinical Specialist</i><br />Center for Family Medicine<br />Cleveland Clinic Akron General<br />Akron, Ohio</p><p><strong>Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA</strong><br /><i>Professor</i><br />Department of Pharmacy Practice<br />College of Pharmacy-Glendale<br />Midwestern University<br />Glendale, Arizona</p><p>Content based on an online CE program supported by an educational grant from Novo Nordisk, Inc.</p><p>Link to full program:<br /><a href="https://bit.ly/3EAARVu" target="_blank">https://bit.ly/3EAARVu</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="78015398" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/6401bfc1-0127-416d-8c10-6588d01dadca/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=6401bfc1-0127-416d-8c10-6588d01dadca&amp;feed=OLtcmjL2"/>
      <itunes:title>Best Practices for Pharmacists to Optimize Use of Obesity Treatment Options and Overcome Barriers to Care</itunes:title>
      <itunes:author>Megan Adelman PharmD BCPS BCGP CDCES, Elizabeth Pogge PharmD MPH BCPS-AQ Cardiology BCGP FASCP FAzPA</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/ffea3fbd-cc74-49aa-adff-9db944aa86f6/3000x3000/pod383-end-obesity-wc-podcast-icon-01.jpg?aid=rss_feed"/>
      <itunes:duration>01:20:58</itunes:duration>
      <itunes:summary>In this podcast episode, Drs Megan Adelman and Elizabeth Pogge review obesity treatment options, with a focus on injectable therapies and overcoming barriers to care.</itunes:summary>
      <itunes:subtitle>In this podcast episode, Drs Megan Adelman and Elizabeth Pogge review obesity treatment options, with a focus on injectable therapies and overcoming barriers to care.</itunes:subtitle>
      <itunes:keywords>obesity, elizabeth pogge pharmd, dual glp-1/gip receptor agonist, pharmacotherapy, glp-1 ra, megan adelman pharmd</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>3</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">bee6b5aa-b8ed-49e2-8aeb-599d879b10e7</guid>
      <title>Management of Anticoagulant-Related Major Bleeding: Clinical Updates and Best Practices for Health-System Pharmacists</title>
      <description><![CDATA[<p><strong>Faculty</strong></p><p>Tyree H. Kiser, PharmD, FCCM, FCCP, BCCCP, BCPS<br />Professor, Department of Clinical Pharmacy<br />University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences<br />Critical Care Pharmacy Specialist, Department of Pharmacy<br />University of Colorado Hospital<br />Aurora, Colorado<br /><br />Charles E. “Kurt” Mahan, PharmD, PhC, FASHP, FCCP<br />Adjunct Associate Professor, Pharmacy<br />University of New Mexico Health Sciences Center<br />Albuquerque, New Mexico<br />  </p><p>Content based on a CE activity supported by an educational grant from Alexion, AstraZeneca Rare Disease.<br />  </p><p>Link to full activity: <a href="https://www.proce.com/Anticoagulation " target="_blank">https://www.proce.com/Anticoagulation</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 7 Jan 2022 15:08:08 +0000</pubDate>
      <author>support@clinicaloptions.com (Tyree H. Kiser PharmD FCCM FCCP BCCCP BCPS, Charles E. “Kurt” Mahan PharmD PhC FASHP FCCP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/management-of-anticoagulant-related-major-bleeding-clinical-updates-and-best-practices-for-health-system-pharmacists-MpBGaZqH</link>
      <content:encoded><![CDATA[<p><strong>Faculty</strong></p><p>Tyree H. Kiser, PharmD, FCCM, FCCP, BCCCP, BCPS<br />Professor, Department of Clinical Pharmacy<br />University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences<br />Critical Care Pharmacy Specialist, Department of Pharmacy<br />University of Colorado Hospital<br />Aurora, Colorado<br /><br />Charles E. “Kurt” Mahan, PharmD, PhC, FASHP, FCCP<br />Adjunct Associate Professor, Pharmacy<br />University of New Mexico Health Sciences Center<br />Albuquerque, New Mexico<br />  </p><p>Content based on a CE activity supported by an educational grant from Alexion, AstraZeneca Rare Disease.<br />  </p><p>Link to full activity: <a href="https://www.proce.com/Anticoagulation " target="_blank">https://www.proce.com/Anticoagulation</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="41304997" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/55ead9cc-b170-4832-8f0a-cb4a24e2f163/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=55ead9cc-b170-4832-8f0a-cb4a24e2f163&amp;feed=OLtcmjL2"/>
      <itunes:title>Management of Anticoagulant-Related Major Bleeding: Clinical Updates and Best Practices for Health-System Pharmacists</itunes:title>
      <itunes:author>Tyree H. Kiser PharmD FCCM FCCP BCCCP BCPS, Charles E. “Kurt” Mahan PharmD PhC FASHP FCCP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/9a6b9d67-7096-496d-ac5c-801628147144/b31fe160-db0b-4f55-8dec-539af2343745/3000x3000/oac-wc-podcasticon.jpg?aid=rss_feed"/>
      <itunes:duration>00:43:01</itunes:duration>
      <itunes:summary>Charles “Kurt” Mahan, PharmD, PhC, FASHP, FCC, and Tyree H. Kiser, PharmD, FCCP, FCCM, BCCCP, BCPS, discuss key takeaways from the live webinar, “Management of Anticoagulant-Related Major Bleeding: Clinical Updates and Best Practices for Health-System Pharmacists” that was presented at the 2021 ASHP conference.</itunes:summary>
      <itunes:subtitle>Charles “Kurt” Mahan, PharmD, PhC, FASHP, FCC, and Tyree H. Kiser, PharmD, FCCP, FCCM, BCCCP, BCPS, discuss key takeaways from the live webinar, “Management of Anticoagulant-Related Major Bleeding: Clinical Updates and Best Practices for Health-System Pharmacists” that was presented at the 2021 ASHP conference.</itunes:subtitle>
      <itunes:keywords>apixaban, idarucizumab, anticoagulants, direct oral anticoagulants, factor xa inhibitors, doacs, dabigatran, doac interruption, major bleeding, rivaroxaban, andexanet</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>2</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">242f4f65-f252-4849-a549-b9c3d3145d27</guid>
      <title>Pharmacists’ Perspective on Managing Multiple Myeloma: FAQs</title>
      <description><![CDATA[<p>1:08 - Take-home thoughts for R/R MM <br />3:47 - Summary of BCMA-targeted CAR T-cell therapy; Use of novel agents for R/R MM<br />6:47 - Information on melphalan flufenamide; Combination approaches with selinexor in clinical practice<br />9:59 - Cost considerations for treatment options in R/R MM<br />12:25 - Administration considerations for subcutaneous daratumumab and venetoclax in R/R MM</p><p><strong>Faculty</strong></p><p>Kathryn Maples, PharmD, BCOP<br />Clinical Pharmacy Specialist, Multiple Myeloma<br />Winship Cancer Institute, Emory Healthcare<br />Atlanta, Georgia<br /><br />Tim Peterson, PharmD, BCOP<br />Clinical Pharmacy Specialist – Multiple Myeloma<br />Memorial Sloan Kettering Cancer Center<br />New York, New York<br /> </p><p>Content based on a CE activity supported by educational grants from Karyopharm Therapeutics, Inc. and Oncopeptides, Inc.</p><p>Link to full activity: <br /><a href="https://www.proce.com/RRMM" target="_blank">https://www.proce.com/RRMM</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 17 Sep 2021 16:07:30 +0000</pubDate>
      <author>support@clinicaloptions.com (Tim Peterson PharmD BCOP, Kathryn Maples PharmD BCOP)</author>
      <link>https://proce-the-pharmacy-practice-podcast.simplecast.com/episodes/pharmacists-perspective-on-managing-multiple-myeloma-faqs-QKS_O9Vl</link>
      <content:encoded><![CDATA[<p>1:08 - Take-home thoughts for R/R MM <br />3:47 - Summary of BCMA-targeted CAR T-cell therapy; Use of novel agents for R/R MM<br />6:47 - Information on melphalan flufenamide; Combination approaches with selinexor in clinical practice<br />9:59 - Cost considerations for treatment options in R/R MM<br />12:25 - Administration considerations for subcutaneous daratumumab and venetoclax in R/R MM</p><p><strong>Faculty</strong></p><p>Kathryn Maples, PharmD, BCOP<br />Clinical Pharmacy Specialist, Multiple Myeloma<br />Winship Cancer Institute, Emory Healthcare<br />Atlanta, Georgia<br /><br />Tim Peterson, PharmD, BCOP<br />Clinical Pharmacy Specialist – Multiple Myeloma<br />Memorial Sloan Kettering Cancer Center<br />New York, New York<br /> </p><p>Content based on a CE activity supported by educational grants from Karyopharm Therapeutics, Inc. and Oncopeptides, Inc.</p><p>Link to full activity: <br /><a href="https://www.proce.com/RRMM" target="_blank">https://www.proce.com/RRMM</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="15447524" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/5f4edab4-c00b-4d55-b328-aa84e46e76c9/episodes/64fc822f-9833-4467-a53c-096c697b38c6/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=5f4edab4-c00b-4d55-b328-aa84e46e76c9&amp;awEpisodeId=64fc822f-9833-4467-a53c-096c697b38c6&amp;feed=OLtcmjL2"/>
      <itunes:title>Pharmacists’ Perspective on Managing Multiple Myeloma: FAQs</itunes:title>
      <itunes:author>Tim Peterson PharmD BCOP, Kathryn Maples PharmD BCOP</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/9a6b9d67-7096-496d-ac5c-801628147144/6393030c-d8c2-4f9a-8017-9f6633ec8d6a/3000x3000/multiple-myeloma-wc-podcasticon.jpg?aid=rss_feed"/>
      <itunes:duration>00:16:05</itunes:duration>
      <itunes:summary>Clinical Pharmacy Specialists Dr. Kathryn Maples and Dr. Tim Peterson answer frequently asked questions on the management of multiple myeloma that include questions on CAR T cell and BCMA-directed therapies as well as supportive care measures and cost considerations.</itunes:summary>
      <itunes:subtitle>Clinical Pharmacy Specialists Dr. Kathryn Maples and Dr. Tim Peterson answer frequently asked questions on the management of multiple myeloma that include questions on CAR T cell and BCMA-directed therapies as well as supportive care measures and cost considerations.</itunes:subtitle>
      <itunes:keywords>b-cell maturation antigen, imids, stomp trial, ocean trial, ixazomib, tumor lysis syndrome, pi, anti-cd38 mabs, lenalidomide, daratumumab, venetoclax, antibody-based therapies, gprc5d, carfilzomib, mm, chimeric antigen t cell, melphalan flufenamide, supportive care, r/r mm, car t, relapsed/refractory multiple myeloma, bispecific t cell engagers, immunomodulatory drugs, bcma, pomalidomide, proteasome inhibitors, multiple myeloma, selinexor, boston trial, dexamethasone, allopurinol</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>1</itunes:episode>
    </item>
  </channel>
</rss>